What Researchers Did
Doctors in Chile reported the case of a Crohn's disease patient with an ischemic ulcer at a surgical reconnection site in the intestine who received HBOT after standard biological therapies failed to achieve remission.
What They Found
The patient showed clinical and endoscopic improvement after receiving HBOT as an add-on treatment. The ischemic ulcer at the ileo-rectal anastomosis responded to the therapy, and the patient's condition improved where other treatments had not succeeded.
What This Means for Canadian Patients
Crohn's disease affects approximately 135,000 Canadians, one of the highest rates in the world. For patients who have had intestinal surgery and developed healing complications or ischemic ulcers at the reconnection site, HBOT may offer a non-surgical option worth discussing with a gastroenterologist.
Canadian Relevance
No direct Canadian connection identified. Canada has among the world's highest rates of inflammatory bowel disease, making this research particularly relevant to Canadian patients.
Study Limitations
This is a single case report from Chile, so it cannot establish that HBOT reliably works for Crohn's disease patients in general.